MEMS-based Inertial Navigation Systems onboard Balloons

Performances of low-cost inertial navigation sensors, usually poor, can often match different mission requirements by means of a careful signal and data processing and/or an augmentation by means of different observables. The paper presents the LOWCOINS navigation experiment, intended to fly onboard BEXUS balloon mission in late 2008. LOWCOINS has as the main component a low-cost three-axes inertial unit, integrating three accelerometers and three gyros. The slow dynamic typical of a balloon flight is deemed as an ideal test to verify the performances of the unit and to improve the knowledge on the data processing needed to obtain an accurate final navigation solution. In order to enlarge the set of available data, a cluster of magnetometers and a pressure sensor, always belonging to low-cost instrumentation range, are hosted on board. Measurements are both stored on board and downlinked to a ground station. Position and velocity components (both the onboard computed first guess and the post-flight calibrated solution) will be compared with the data gathered by a GPS receiver, which is a standard component of BEXUS balloon avionics. Substantial attention to thermal aspects has been requested in order to cope with environmental conditions prior of and all along the flight. The requested navigation unit case design is shortly reported

Anaerobic biodegradation of cassava wastewater under different temperatures and inoculums.

The production of starch generates, as a by-product, the cassava wastewater (manipueira), which can be treated by anaerobic digestion to provide biogas and minimize its polluting potential. The most commonly utilized biomass in the anaerobic digestion is the anaerobic sludge. The literature presents, as an alternative to sludge, bovine manure and ruminal fluids, being scarce the studies with the cassava wastewater. This research evaluated the influence of temperature on the microbial ability of cattle and goat rumen in anaerobically biodegrading the manipueira in substitution to the anaerobic sludge. The cattle and goat rumen specific methanogenic activities (SMA) were compared with that of the anaerobic sludge. Subsequently, by using the inoculum which had the best SMA results, cassava wastewater biodegradability tests were performed, investigating the kinetics of the organic matter removal and methane production at 32 ° C and 39 ° C. The bovine rumen presented better results in the SMA (0,315 g COD-CH4 g VSS.d-1) and methane production (1,026 mL). The temperature of 32 °C did not influence the activity of bovine ruminal inoculum as the kinetics of the biodegradation of the manipueira did not differ for the evaluated temperatures (0.1799 d-1 at 32°C and 0.1781 d-1 at 39°C). Bovine rumen achieved glucose reduction of 76% and 80% and methane yield of 77% and 79% for the tests at 32°C and 39°C, respectively. It is inferred that this type of inoculum might be used in reactors of anaerobic digestion processes for the treatment of the cassava wastewater at the ambient temperature of the semiarid region

On the Dynamics of solitons in the nonlinear Schroedinger equation

We study the behavior of the soliton solutions of the equation i((\partial{\psi})/(\partialt))=-(1/(2m)){\Delta}{\psi}+(1/2)W_{{\epsilon}}'({\psi})+V(x){\psi} where W_{{\epsilon}}' is a suitable nonlinear term which is singular for {\epsilon}=0. We use the "strong" nonlinearity to obtain results on existence, shape, stability and dynamics of the soliton. The main result of this paper (Theorem 1) shows that for {\epsilon}\to0 the orbit of our soliton approaches the orbit of a classical particle in a potential V(x).Comment: 29 page

Investigation into the High Voltage Shutdown of the Oxygen Generator System in the International Space Station

The Oxygen Generation System (OGS) Hydrogen Dome Assembly Orbital Replacement Unit (ORU) serial number 00001 suffered a cell stack high-voltage shutdown on July 5, 2010. The Hydrogen Dome Assembly ORU was removed and replaced with the on-board spare ORU serial number 00002 to maintain OGS operation. The Hydrogen Dome Assembly ORU was returned from ISS on STS-133/ULF-5 in March 2011 with test, teardown and evaluation (TT&E) and failure analysis to follow

Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells

Background and Objective. Allogeneic bone marrow transplantation remains the only potentially curative treatment for CML, but more than 70% of patients will be ineligible for allogeneic marrow transplant either because they do not have a suitable HLA-matched related or unrelated donor or because they are more than 50 years old. Several experimental and clinical findings support a role for autologous stem cell transplantation (ASCT) in CML. It has been suggested that in the early phase following autografting the Ph-negative clone has a proliferative advantage over the Ph-positive clone. We hypothesized that post-transplant GM-CSF administration could reactivate the functional activity of quiescent normal progenitors and prolong the duration of the post-transplant proliferative advantage of Ph-negative over Ph- positive progenitors. In order to evaluate the effect of post-transplant GM- CSF administration, a pilot clinical study was performed in which CML patients resistant to IFN-α therapy were autografted with unmanipulated marrow or blood cells and given prolonged GM-CSF therapy post-transplant. Methods. Five adult CML patients conditioned with the BAVC regimen were reinfused with either marrow (n=2) or blood (n=3) cells and given granulocyte-macrophage colony-stimulating factor (GM-CSF). Recombinant GM- CSF was initially administered at standard dosage (5 pg/kg/day) until a white blood cell count ≤2x109/L was achieved on two consecutive examinations, and thereafter at a low dose (1 μg/kg/day) for 5 to 9 months. On a weekly basis, GM-CSF was discontinued and hydroxyurea (1,000 mg/d) was given for two days. Results. Evidence of trilineage engraftment was observed in all cases. At autografting, 3 out of the 5 patients revealed 8-9% Ph-negative metaphases. During the initial phase of hematopoietic regeneration, direct cytogenetic analysis revealed 81% and 100% Ph-negative metaphases in two cases; nonleukemic hematopoiesis progressively decreased and was no longer detectable at +9 months. One patient showed cyclic Ph-negative hematopoiesis that appeared 3 months following autografting and peaked at +4 and +8 months. The fourth patient showed a low percentage (20%) of Ph-negative metaphases 1 month after ASCT, followed by a significant expansion of nonleukemic hematopoiesis, which could be detected up to month +13. No evidence of Ph- negative hematopoiesis could be detected in one patient. Three patients are in chronic phase 28, 30 and 31 months after autografting, respectively, and two patients evolved into blast crisis. Interpretation and Conclusions. This pilot study demonstrates that combined GM-CSF and hydroxyurea therapy seems to be effective in inducing and/or prolonging a transient period of Ph- negative hematopoiesis. The late appearance of Ph-negative hematopoiesis detected in two patients suggests an antileukemic activity of the combined GM-CSF/hydroxyurea therapy rather than an antileukemic effect of the conditioning regimen

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

In multiple myeloma, novel treatments with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) have prolonged survival but the disease remains incurable. At relapse, next-generation sequencing has shown occasional mutations of drug targets but has failed to identify unifying features that underlie chemotherapy resistance. We studied 42 patients refractory to both PIs and IMiDs. Whole-exome sequencing was performed in 40 patients, and RNA sequencing (RNA-seq) was performed in 27. We found more mutations than were reported at diagnosis and more subclonal mutations, which implies ongoing evolution of the genome of myeloma cells during treatment. The mutational landscape was different from that described in published studies on samples taken at diagnosis. The TP53 pathway was the most frequently inactivated (in 45% of patients). Conversely, point mutations of genes associated with resistance to IMiDs were rare and were always subclonal. Refractory patients were uniquely characterized by having a mutational signature linked to exposure to alkylating agents, whose role in chemotherapy resistance and disease progression remains to be elucidated. RNA-seq analysis showed that treatment or mutations had no influence on clustering, which was instead influenced by karyotypic events. We describe a cluster with both amp(1q) and del(13) characterized by CCND2 upregulation and also overexpression of MCL1, which represents a novel target for experimental treatments. Overall, high-risk features were found in 65% of patients. However, only amp(1q) predicted survival. Gene mutations of IMiD and PI targets are not a preferred mode of drug resistance in myeloma. Chemotherapy resistance of the bulk tumor population is likely attained through differential, yet converging evolution of subclones that are overall variable from patient to patient and within the same patient